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Results of multigene panel testing 
in familial cancer cases without 
genetic cause demonstrated by 
single gene testing
Mev Dominguez-Valentin  1*, Sigve nakken  1,13, Hélène tubeuf2,3, Daniel Vodak1, 
per olaf ekstrøm1, Anke M. nissen4,5, Monika Morak4,5, elke Holinski-feder4,5, Arild Holth6, 
Gabriel capella7, Ben Davidson6,8, D. Gareth evans9,10, Alexandra Martins  2, pål Møller1,11 & 
eivind Hovig  1,12
We have surveyed 191 prospectively sampled familial cancer patients with no previously detected 
pathogenic variant in the BRCA1/2, PTEN, TP53 or DNA mismatch repair genes. In all, 138 breast cancer 
(BC) cases, 34 colorectal cancer (CRC) and 19 multiple early-onset cancers were included. A panel of 
44 cancer-predisposing genes identified 5% (9/191) pathogenic or likely pathogenic variants and 87 
variants of uncertain significance (VUS). Pathogenic or likely pathogenic variants were identified 
mostly in familial BC individuals (7/9) and were located in 5 genes: ATM (3), BRCA2 (1), CHEK2 (1), 
MSH6 (1) and MUTYH (1), followed by multiple early-onset (2/9) individuals, affecting the CHEK2 and 
ATM genes. Eleven of the 87 VUS were tested, and 4/11 were found to have an impact on splicing by 
using a minigene splicing assay. We here report for the first time the splicing anomalies using this 
assay for the variants ATM c.3806A > G and BUB1 c.677C > t, whereas CHEK1 c.61G > A did not 
result in any detectable splicing anomaly. Our study confirms the presence of pathogenic or likely 
pathogenic variants in genes that are not routinely tested in the context of the above-mentioned 
clinical phenotypes. interestingly, more than half of the pathogenic germline variants were found in 
the moderately penetrant ATM and CHEK2 genes, where only truncating variants from these genes are 
recommended to be reported in clinical genetic testing practice.
Based on twin studies and recent reports, 30–45% of colorectal cancer (CRC) cases may involve a heritable com-
ponent1–4. However, highly-penetrant pathogenic germline variants that explain familial aggregation and/or an 
early-onset of the disease (e.g. pathogenic variants in APC and DNA mismatch repair (MMR) genes) are detected 
in only 5–10% of the cases5. In contrast, in hereditary breast and ovarian cancer (HBOC), up to ~25% of the cases 
can be explained by the highly penetrant risk genes BRCA1 and BRCA26.
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Next-generation sequencing (NGS) studies have reported that as many as ~18% of patients diagnosed with 
CRC < age of 50 years have pathogenic germline variants in genes that are not traditionally associated with CRC, 
including ATM, CHEK2, BRCA1, BRCA2, CDKN2A or PALB27,8, while up to 15% of HBOC patients harbor path-
ogenic variants in known BC predisposing genes, including RAD51C, RAD51D, ATM, CHEK2, BRIP1, PALB2, 
BARD1, RECQL, TP53, CDH1 and NBN9,10. Hence, in approximately 60%-70% of all tested hereditary CRC or 
HBOC patients, the genetic predisposition is still unknown. There is a need to determine whether these variants 
contribute to hereditary CRC or HBOC risk via the combination of low- and moderate-penetrance susceptibility 
alleles, or in conjunction with environmental factors7,8,11–13
Importantly, phenotype-driven panels provide a notable rate of detection of pathogenic variants with clinical 
actionability. NGS-based panel screening described 8–13% of pathogenic variants in BRCA1/2 negative HBOC 
patients14,15. Therefore, there are new genes recently discovered by the use of gene panel testing for which there is 
still limited data regarding the degree of their association to cancer risk, and the medical management guidelines 
are scant or non-existent for some of them16–18.
A relatively common event that complicates the interpretation of gene test results is the detection of variants 
of unknown significance (VUS). Regarding BRCA1 and BRCA2 genes, up to 20% of all variants are still being 
classified as VUS19, while about one-fifth to one-third are classified in the case of the DNA MMR gene variants20.
Because multiple cancer gene panel testing is rapidly replacing sequential single-gene testing, we need to know 
how to improve in the way we interpret the findings from panel testing patients in cancer kindreds who have been 
previously tested for the BRCA1/2, PTEN, TP53 and MMR genes without detection of pathogenic variants. The 
goals were to gain information on to which degree other genes may have been causative for cancer in the patients 
and their relatives, and to be informed on how such genes were deranged to discriminate between normal and 
disease-causing variants. In addition, we analyzed the impact of a subset of VUS on RNA splicing by the use of 
minigene assays.
Methods
The methods were performed in accordance with the relevant guidelines and regulations.
Study population. The study population was selected from the Hereditary Cancer Biobank (n = 161), 
which is part of the out-patient inherited cancer clinic from the Norwegian Radium Hospital (Norway)21 and the 
Department of Genomic Medicine (n = 30) from the University of Manchester (United Kingdom)12.
The selection criteria for the 191 individuals were as follows:
•	 Being member of cancer family or having a personal history of cancer;
•	 Presence of multiple early-onset cancer at early age of onset, including BC, gynecological cancer, CRC, or 
thyroid cancer;
•	 Familial CRC cases: Families that fulfilled the Amsterdam criteria or the revised Bethesda guidelines who had 
tested negative for pathogenic variants in the mismatch repair (MMR) genes;
•	 Familial BC cases: Women with BC or gynecological cancer who had tested negative for pathogenic BRCA1 
or BRCA2 variants.
Overall, our study subjects (n = 191) were demonstrated not to carry pathogenic variants in BRCA1/2, TP53, 
PTEN or MMR genes, or large exon deletions/duplications involving these genes by standard diagnostics.
In all, 138 breast cancer (BC) cases were included, where 57 were denoted as BRCA phenocopies (cases who 
were tested negative for their respective family’s path_BRCA1 (n = 18) and path_BRCA2 variants (n = 39)). 
Thirty-four CRC and 19 multiple early-onset cancers cases were also included (Fig. 1). Out of the 191 familial 
cancer patients, we have previously reported on 95 individuals (48 phenocopies, 34 familial CRC and 13 multiple 
early-onset cases)12,22,23. The current study added 96 new cases, including 81 familial BC cases, 9 phenocopies and 
6 additional subjects having multiple early-onset cancer (Fig. 1).
Ethical approval for the study was granted by the Norwegian Data Inspectorate (ref. 2001/2988-2) and Ethical 
Review Board (ref. S-02030). All examined patients signed an informed consent for their participation in the 
study.
Figure 1. Relational flowchart of the cancer kindreds and results from the study.
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targeted sequencing and data analysis. Genomic DNA was isolated from peripheral blood samples 
and a 44-gene panel targeted sequencing was carried out using a TruSeq amplicon-based assay v.1.5 on a MiSeq 
apparatus (Supplementary Table 1)12,22,23. The mean depth of sequencing coverage ranged from 124 to 535, and 
the fraction of target bases with coverage ≥25 ranged from 80% to 94%.
Sequence alignments with paired-end sequence reads to the human reference genome (build GRCh37) were 
obtained through the BWA-mem algorithm (v.0.7.8-r55), where sorting and indexing procedures were under-
taken with Samtools (v.1.1). Genotyping of single nucleotide variants (SNV) and short indels, as well as quality 
filtering of the raw genotype calls, were done according to GATK’s best practice procedures, as described previ-
ously in more detail12,22,23.
Functional annotation of the variants was performed with ANNOVAR (version November 2015)24 and using 
five databases (gnomAD, dbSNP (build 147)25, 1000 Genome Project phase326, UniProt (release March 2016)27, 
and Pfam protein domain (v29, December 2015)12,22,23,28.
Nomenclature and classification of genetic variants. The Human Genome Variation Society (HGVS) 
guidelines were used to describe the detected genetic variants29. The following databases: Evidence-based 
Network for the Interpretation of Germline Mutant Alleles (ENIGMA), Breast Cancer Information Core (BIC), 
International Society of Gastrointestinal Hereditary Tumors (InSiGHT), Leiden Open Variation Database 
(LOVD), ClinVar, and the Human Gene Mutation Database (HGMD) were interrogated for the clinical signifi-
cance of the identified genetic variants (in their releases as of August 2018).
We applied the American College of Medical Genetics and Genomics (ACMG) guidelines for the classification 
and interpretation of the clinical significance of the variants30. In addition, when a novel variant was identified in 
the study, we considered it to be pathogenic or likely pathogenic if either one of the following criteria were met: a) 
introduction of a premature stop codon in the protein coding sequence (nonsense or frameshift); b) occurrence 
at positions +1/+ 2 or −1/−2 of donor or acceptor splice sites, respectively; or c) whole-exon deletions.
Validation by cycling temperature capillary electrophoresis. Cycling temperature capillary elec-
trophoresis was used to validate the 13 pathogenic variants found in the study. The method has been previously 
described12,31–33. The variant melting profile tool (http://meltprimer.ous-research.no/)34 was used to design the 
amplicons. Details about the primer sequences, PCR reaction conditions and electrophoresis settings are available 
upon request.
In silico analyses of VUS. The MaxEntScan (MES) and SSF-like (SSFL) methods were used to predict 
variant-induced alterations in 3′ and 5′ splice site (3′ss and 5′ss) strength, as described by Houdayer et al. 201235, 
but using the integrated software tool Alamut Batch version 1.5 (Interactive Biosoftware, France). As previously 
described by Soukarieh et al.36 and in prior studies12,22,23, we considered:
•	 If ΔMES ≥ 15% and ΔSSFL ≥ 5%: the variant mapping at a splice site could negatively impact exon 
inclusion35;
•	 If negative Δ scores were provided by at least 2 out of the 3 exonic splicing regulatory elements (ESR)-dedi-
cated in silico tools: the variant located outside the splice sites was considered as a probable inducer of exon 
skipping36.
The Align-GVGD (the VUS were predicted as deleterious when the values were C35 or higher), SIFT, MAPP, 
PolyPhen-2 and MutationTaster12,22,23,37–41 were used to predict the protein impact of missense variants. The 
Alamut Batch version 1.4.4 (Interactive Biosoftware, http://www.interactive-biosoftware.com) was used for the 
protein in silico predictions.
cell-based minigene splicing assay. We performed functional assays based on comparative analysis of 
the splicing pattern of wild type (WT) and mutant reporter minigenes to analyze the impact on splicing of each 
selected variant, as previously reported12,22,23.
The genomic regions containing the exon of interest and ~150 nucleotides of the flanking introns were ampli-
fied by PCR using patients’ DNA as template and primers (Supplementary Table 2). The PCR-amplified frag-
ments were inserted into a previously linearized pCAS2 vector, generating the representative minigenes. The 
inserts of all clones were sequenced and the WT and mutant constructs were transfected in parallel into HeLa 
cells grown at ~70% confluence. The total RNA was extracted after 24 h, and the transcripts were analyzed by 
semi-quantitative RT-PCR (Supplementary Table 2). The RT-PCR products were separated by electrophoresis, 
followed by gel-purification. Sanger sequencing was performed for the proper identification of the minigene 
transcripts. Finally, fluorescent RT-PCR reactions followed by capillary electrophoresis were performed to quan-
tify the splicing events. The computational analysis was performed using GeneMapper v5.0 software (Applied 
Biosystems).
Immunohistochemistry of ATM c.3806A > G carrier. We assessed in situ the effect of ATM c.3806A > G 
p.(Lys1269Arg) at the protein level by performing an immunohistochemistry (IHC) analysis. Paraffin-embedded 
material from the patient tumor was immuno-stained for the ATM protein: Briefly, 4-µm sections were placed on 
SuperFrost® Plus microscope slides. Antigen retrieval was performed in a Dako PT Link in Dako’s pH 6 (Low pH) 
retrieval solution according to the Dako’s Flex protocol and stained manually. We used the anti-ATM antibody 
clone 2C1 (Abcam ab78, dilution 1:2000). The ATM protein expression was assessed either as retained (normal), 
absent, or weak (i.e. tumor cell staining intensity was reduced compared with that of the normal internal control).
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Results
Pathogenic or likely pathogenic germline findings. We utilized a 44-cancer gene panel in 191 high-
risk individuals in order to identify other high- or moderate- penetrance genes that could be implicated in the 
genetic cause of these phenotypes (Supplementary Table 1). In the combined cohort, we identified 9 cases (5% of 
191) who carried 9 pathogenic or likely pathogenic variants that were confirmed by cycling temperature capillary 
electrophoresis, showing 100% concordance (Fig. 1, Table 1).
From high- to moderate-penetrance genes identified in the study. Two pathogenic variants (2/191, 
1%) were identified in high-penetrance genes, namely BRCA2 c.9382C > T p.(Arg3128*) (this variant was previ-
ously undetected, as only the path_BRCA2 c.6591_6592delTG was demonstrated in a relative subjected to previ-
ous testing) and MSH6 c.3261delC (p.Phe1088Serfs*2) from two phenocopy individuals.
In the case of the heterozygous MUTYH c.1178G > A (p.Gly393Asp), we reported this gene as a recessive risk 
and it was found in a phenocopy individual, as previously reported by us12 (Table 1, Fig. 2A).
Six pathogenic variants (6/191, 3.1%) were detected in moderate-penetrance genes and included: ATM 
c.9139C > T (p.Arg3047*) and ATM c.468G > A (p.Trp156*) found in two phenocopies cases12, the Norwegian 
founder ATM c.3245_3247delinsTGAT (p.His1082Leufs)42, and the ATM c.8432delA (p.Lys2811Serfs*46) found 
in familial BC and multiple early-onset case, respectively. In addition, we identified CHEK2 c.319 + 2T > A 
(IVS2 + 2T > A in multiple early-onset and familial BC cases (Fig. 2A).
pathogenic or likely pathogenic variants by clinical phenotype. When analyzed by clinical phe-
notype, we described that phenocopies and familial BC patients are the most affected cohorts by the presence of 
pathogenic variants in high- and moderate-penetrance genes, respectively. In detail, phenocopies were affected 
by the presence of pathogenic variants in the high-penetrance genes BRCA2 and MSH6, the moderate-penetrance 
gene: ATM and MUTYH gene. Familial BC cases were predominately affected by pathogenic or likely pathogenic 
variants in moderate-penetrance (ATM, CHEK2) genes (Fig. 2B).
In silico and minigene analysis of VUS. In addition to the 9 pathogenic variants found in the study, the 
NGS results revealed the presence of 87 variants that we interpreted as VUS. When in silico splicing and protein 
predictions were applied, 17 VUS in 15 genes were selected as more likely to be functionally relevant: APC, ATM, 
AXIN2, BRCA2, BUB1, CDH1, CHEK1, CHEK2, MAP3K1, MSH2, NOTCH3, POLE, RAD51B, RAD51D, and 
STK11 (Supplementary Table 3). The MAF of these variants in the gnomAD database were very low (<1%) or not 
reported (Supplementary Table 3). Given that patient RNA was not available, we decided to experimentally assess 
the impact on splicing of the 17 VUS by performing cell-based minigene assays. Because of technical difficulties, 
6 variants were excluded from the analysis (Supplementary Table 3).
An overview of the results for the remaining 11 VUS is shown in Supplementary Table 3, which includes data 
for 8 variants that we have published elsewhere. More precisely, we previously reported that APC c.721G > A, 
BRCA2 c.116C > T, CDH1 c.1774G > T, CHEK2 c.608A > G MAP3K1 c.764A > G and NOTCH3 c.5854G > A 
did not affect the splicing pattern of the minigene transcripts12,22, whereas MSH2 c.815C > T and NOTCH3 
c.1490C > T were previously described to induce partial skipping of exons 5 and 9, respectively22,43. Here, we 
Genetic Variant Penetrance of the gene* Cancer type
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ATM (NM_000051) c. 









Moderate-penetrance Familial BC Pathogenic/Pathogenic Current study
ATM (NM_000051) c.468G > A 
(p.Trp156*) Moderate-penetrance Phenocopies Not described/Pathogenic
Dominguez-
Valentin et al., 
2018
ATM (NM_000051) c.8432delA 
(p.Lys2811SerfsTer46) Moderate-penetrance
Multiple early 
onset Pathogenic/Pathogenic Current study
BRCA2 (NM_000059) 
c.9382C > T (p.Arg3128Ter) High-penetrance Phenocopies Pathogenic/Pathogenic
Dominguez-
Valentin et al., 
2018
CHEK2 (NM_007194) 




Valentin et al., 
2017
CHEK2 (NM_007194) 
c.319 + 2T > A Moderate-penetrance Familial BC Likely Pathogenic/Pathogenic Current study
MSH6 (NM_000179) c.3261del 
(p.Phe1088SerfsTer2) High-penetrance Phenocopies Pathogenic/Pathogenic
Dominguez-
Valentin et al., 
2018
MUTYH (NM_012222) 




Valentin et al., 
2018
Table 1. Description of the 9 pathogenic or likely pathogenic variants found in phenocopies, familial BC 
and multiple early-onset cancers cases analyzed by 44-cancer gene panel testing. BC: breast cancer; ACMG: 
American College of Medical Genetics and Genomics, *Dominguez-Valentin et al.22.
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report that ATM c.3806A > G induces a complex pattern of aberrant splicing as described below (Fig. 3A–D). 
Moreover, we found that BUB1 c.677C > T causes a moderate increase in exon skipping, whereas CHEK1 
c.61G > A has no major effect in the context of our minigene assay (Fig. 3B).
ATM c.3806A > G, BUB1 c.677C > T and CHEK1 c.61G > A. In the ATM gene, we identified a transi-
tion A > G at position c.3806 in the exon 26 (c.3806A > G, p.(Lys1269Arg), rs146017595) in a woman with a BC 
diagnosis at 46 years. The pedigree indicated a family history of BC, ovarian cancer and colon cancer, including a 
mother with BC diagnosis at 56 years, and two maternal aunts with BC diagnoses at 43 and 46 years, respectively 
(data not shown). To our knowledge, ATM c.3806A > G (p.Lys1269Arg) has not been classified in the literature 
either as pathogenic or benign. The variant is present in the general population at a very low allele frequency 
according to the gnomAD database (6.668 e-05) and is reported in ClinVar as a VUS (Variation ID: 185981). 
RNA splicing-dedicated in silico analyses predicted that this variant may affect RNA maturation by modifying 
potential splicing signals within ATM exon 26 (Supplementary Table 3). Our minigene assay results, shown in 
Fig. 3, revealed that ATM c.3806A > G indeed causes aberrant splicing, leading to a decrease in full-length tran-
scripts (from 95% to 23%). Two main aberrant isoforms were detected in this assay: one presenting a terminal 
deletion of 192 nucleotides (corresponding to ATM r.3802_3993del, p.Val1268_Glu1331del) and the other pre-
senting an internal deletion of 102 nucleotides within ATM exon 26 (corresponding to ATM r.3803_3904del, 
p.Val1268_1301del). Both alterations result from the usage of a new splice site directly introduced by the variant 
as predicted by the MaxEntScan algorithm (Supplementary Table 3). The terminal deletion indicates that the 
new 5′ ss can, in some transcripts, outcompete the natural 5′ss of exon 26 and be spliced to the following exon, 
whereas the internal deletion shows that ATM c.3806A > G also leads, in part, to the activation of a cryptic 3′ss 
downstream in exon 26 (Fig. 3D). Protein-based in silico analyses were inconsistent regarding the effect that ATM 
c.3806A > G (p.Lys1269Arg) may have on protein structure and function (Supplementary Table 3). We assessed 
in situ the effect at the protein level of ATM c.3806A > G by IHC analysis. The results revealed a weak-to-absent 
staining in the proband’s tumor as compared to normal surrounding tissue (Fig. 3E–G), also suggesting that the 
germline ATM c.3806A > G may be implicated in tumor development.
The BUB1 c.677C > T variant was identified in a female with a BC diagnosis at 56 years who did not carry any 
pathogenic variant in BRCA1/2 or MMR genes. In addition to the BUB1 variant, the patient carried two class 1/2 
variants: NOTCH3 c.1487C > T (p.Pro496Leu) and NOTCH3 c.3704A > T (p.His1235Leu). The BUB1 variant is 
present in the general population at a low allele frequency according to the gnomAD database (1.999 e-3), and 
has not been reported in ClinVar. As ATM c.3806A > G, the protein-based in silico analyses were inconsistent 
regarding the effect on protein structure and function for BUB1 c.677C > T (Supplementary Table 3). The mini-
gene assay showed a moderate increase in exon skipping (43% to 61%) (Fig. 3B).
Finally, we identified a CHEK1 c.61G > A in a BRCA2 phenocopy case, which is currently not reported in 
ClinVar, and the minigene assay showed no major splicing defect, which is in contrast to the in silico predictions 
(Fig. 3B).
Figure 2. Overview of the germline variants found in the study. (A) Type of the pathogenic or likely pathogenic 
variants found in 191 multiple early-onset and familial cancers from multigene NGS. (B). Distribution of 
pathogenic or likely pathogenic variants by clinical phenotype
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Figure 3. Detection of variant-induced splicing alterations by using a minigene splicing assay. (A) Structure 
of pCAS2 minigenes used in this assay. The gray arrow indicates the CMV promoter, boxes represent exons, 
lines in between indicate introns, and arrows below the exons represent primers used in RT-PCR reactions. 
The start indicates a fluorescent primer. (B) Analysis of the splicing pattern of the pCAS2-derived minigenes 
carrying ATM, BUB1 and CHEK1 variants as indicated. The minigene assays were performed as described 
under Materials and Methods. The top panel shows the RT-PCR products obtained for WT and mutant 
constructs separated by electrophoresis on an ethidium bromide–stained 2.5% agarose gel. The bottom panel 
shows the quantification of the RT-PCR products focusing on the relative level of exon inclusion (i.e. products 
corresponding to full-length minigene transcripts, FL). Quantification was performed after separating the 
fluorescent RT-PCR products by capillary electrophoresis on an automated sequencer. as described under 
Materials and Methods. (C) Representative fluorescent RT-PCR experiment using pCAS2 minigenes carrying 
ATM exon 26 (WT and c.3806A > G, as indicated). The panel shows superposed peaks corresponding to the 
WT and mutant RT-PCR products (in blue and red, respectively). Splicing events are expressed as % of the total 
amount of RT-PCR products obtained for each WT and mutant minigene construct (mutant vs WT). Results 
are representative of two independent experiments. (D) Splice sites-dedicated bioinformatics predictions and 
representation of the major splicing events detected in the minigene assay relative to ATM exon 26. The position 
of c.3806A > G is indicated by the red circle. In silico predictions of splice sites were obtained by simultaneously 
interrogating 5 algorithms (SpliceSiteFinder-Like, MaxEntScan, NNSPLICE, GeneSplicer and Human Splice 
Finder) through the integrated software Alamut Visual Version 2.10 (Interactive Biosoftware, France). For 
simplicity, only scores relative to ATM 5′ss and 3′ss (natural, de novo or cryptic sites) detected in the minigene 
assay are shown. The properly spliced full-length exon (FL) is represented above the panel whereas the 
aberrantly spliced truncated versions of the exon are indicated underneath. (E) Immunohistochemical staining 
for ATM in the patient’s tumor. (F) Breast carcinoma control. (G) Malignant effusions from other cancer cases. 
Host cells, consisting of lymphocytes, macrophages, stromal cells and adipocytes, are strongly positive. The 
tumor was immunostained for the ATM protein as follows. Briefly, 4-µm sections were placed on SuperFrost® 
Plus microscope slides. Antigen retrieval was performed in a Dako PT Link in Dako’s pH 6 (Low pH) retrieval 
solution according to the Dako´s Flex protocol and stained manually. We used the anti-ATM antibody clone 
2C1 (Abcam ab78, dilution 1:2000). The ATM protein expression was assessed as retained (normal), absent, or 
weak (i.e. tumor cell staining intensity was reduced compared with that of the normal internal control).
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Discussion
When applying multigene panel testing to a set of 191 familial cancer cases, we identified 9 cases (5%) harboring 
pathogenic or likely pathogenic variants. Most of these variants (4.2%, 8/191) were identified in the moderate to 
high penetrance genes BRCA2, MSH6, CHEK2 and ATM. The detection rate in these core genes is comparable to 
previous reports14,15. We also detected a likely pathogenic variant in MUTYH, for which there is still insufficient 
evidence for a significant risk of BC.
Interpreting the pathogenicity significance of moderate- or low- penetrance variants is a challenge for current 
cancer risk management, counselling and treatment decision-making regarding patients and their families. In 
this regard, Lynch syndrome (LS) is an autosomal dominant condition caused by pathogenic variants in one of 
the MMR genes, which result in different cancer risks. Path_MLH1 and path_MSH2 variants are highly penetrant 
when comparing to path_MSH6 and path_PMS2 variants44–46. Regarding BRCA genes, we have recently described 
that the most frequent path_BRCA1 variants in the Norwegian population had low penetrance in fertile ages, and 
lower than in carriers of infrequent path_BRCA1 variants47. The relative risk of developing BC has been described 
for truncating variants in BRCA2 (relative risk: 11.7), while ATM and CHEK2 truncating variants have relative 
risks of 2.8 (2.2–3.7) and 3.0 (2.6–3.5), respectively48.
A recent evaluation of gene-disease associations using the ClinGen clinical validity framework revealed defin-
itive assertion for ATM and CHEK2 genes in breast cancer49. Our results are in agreement for the pathogenic vari-
ants found in the ATM (n = 3) and CHEK2 (n = 1) genes which were found in phenocopies or familial BC cases49.
There is still no clear evidence of an association between BC and other DNA repair genes, such as MLH1, 
MSH2, MSH6 and MAP3K1 genes. An average moderate-risk colorectal screening based on family history has 
been suggested for individuals with a heterozygous germline MUTYH pathogenic variant50,51.
Approximately 25% of missense and nonsense variants disrupt mRNA splicing, and the understanding of 
functional splice variations may allow the (re)classification of VUS in CRC and other BC-associated genes. In 
a recent retrospective study, among variants initially classified as VUS, 7.7% were reclassified (91% were down-
graded to class 1/2 and 9% were upgraded class 4/5) and 8.7% were upgraded to class 4/552.
Out of the 87 variants of VUS, 11 were tested by a minigene splicing assay, out of which two (ATM c.3806A > G 
and BUB1 c.677C > T) were demonstrated to exert an effect on splicing. The ATM c.3806A > G variant was iden-
tified in an early-onset BC patient (<50 years) with a strong BC, ovarian and colon cancer family history. Our 
minigene assay results suggested that this variant partially alters the splicing pattern of ATM, leading to the 
concomitant production of aberrant transcripts presenting in-frame deletions in exon 26 and a decreased expres-
sion of full-length transcripts carrying the c.3806A > G (p.Lys1269Arg) variant. Although these experimental 
findings agree with RNA-splicing-dedicated in silico predictions, and minigene results are often concordant with 
in vivo data43,53,54, it will be essential to confirm our experimental results by analyzing RNA from patient samples. 
However, no RNA from the peripheral blood nor from the tumor of this patient, nor the other patients, were 
available for analysis. Our IHC results suggest that ATM c.3806A > G is associated with tumor development in the 
index patient. However, segregation data may provide additional evidence to classify this variant.
There is no clinical significance reported for the BUB1 c.677C > T variant. BUB1 encodes a serine/
threonine-protein kinase that plays a central role in mitosis55, and pathogenic variants in this gene have been 
associated with aneuploidy and several forms of cancer. However, a recent study does not support the inclusion 
of BUB1 and BUB3 testing in routine genetic diagnostics of familial CRC and polyposis56. Our minigene assay 
showed a moderate increase in exon skipping due to the BUB1 c.677C > T variant, that remains classified as a 
VUS.
Information about ATM c.3806A > G and BUB1 c.677C > T variants in the spectrum of BC studies using NGS 
panel testing is currently scarce. In this scenario, not only functional or protein assays, but also co-segregation 
studies, will be essential for understanding whether the VUS analyzed in this work have causal or modifying 
effects, or otherwise are non-pathogenic. Importantly, there is no systematic classification for most of the genetic 
variants found by NGS, including the ATM c.3806A > G and BUB1 c.677C > T identified in this study, and, in 
more general terms, the impact of pathogenic variants in low- to moderate-penetrance genes is not fully under-
stood with respect to clinical management. Most of the VUS may in the future be reclassified as deleterious or 
benign, but in the meantime, they cannot be used to make clinical decisions22.
There is a need to understand and quantify the cancer risk of pathogenic and currently uncertain variants 
found in moderate- or low- penetrance genes. A quantitative approach to prioritize missense substitutions with 
high probabilities of pathogenicity has been suggested for the ATM, CHEK2 and NBN genes57. However, there is 
still a high number of novel variants with an unknown significance of pathogenicity identified in cancer patients 
with family history awaiting classification. The evaluation of clinical, family parameters, functional assay and 
IHC analyses undertaken in this study may allow to refine the clinical classification of these variants. To the latter 
end, broad collaborations to compile data from different sources are needed to arrive at conclusions, and, we here 
contribute our results towards that end.
conclusion
Five percent of 191 families initially tested by clinical diagnostic settings, were found to carry pathogenic variants 
in the ATM, MSH6, BRCA2, MUTYH and CHEK2 genes, when using a 44-gene panel. We further provided func-
tional testing and protein characterization in addition to clinical and family history information.
Our study contributes to understanding and interpreting variants in moderate- or low-penetrance genes 
which are not routinely tested in the clinical genetic settings and may have a direct impact on providing an appro-
priate genetic counseling and clinical management for individuals and their relatives who carry these variants.
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